Grants, Giving & Corporate Sponsorship Support
Bristol Myers Squibb is committed to supporting appropriate independent requests for funding and in-kind support to non-profit third party organisations which make a difference to people’s lives either directly or indirectly through healthcare related support, medical and scientific education, research and general community based charitable activities.
Corporate Giving
Corporate giving is one of three major ways Bristol Myers Squibb supports worthwhile causes and conscientious citizenship.
- Charitable Donations and in-kind Support
- Independent Medical Education
- Scholarship Support
- Fellowship Support
- Patient Education Grant
- Corporate Sponsorship for events, activities and initiatives which contribute to scientific exchange, or demonstrate a commitment to patients or communities
- Umbrella Research Grants (Funds provided to an institution/organisation to support scientific research programmes in a broad area related to a Bristol Myers Squibb therapeutic area of interest). Umbrella Research Grants are distinct from Investigator Sponsored Research - ISRs.
The Application Process
In order to be considered, organisations will need to meet Bristol Myers Squibb internal business conduct and ethics criteria as embodied in the BMS “Principles of Integrity”, together with the Association of the British Pharmaceutical Industry (ABPI), the Medicines and Healthcare products Regulatory Agency (MHRA) Regulations, as well as other relevant Legal and Regulatory requirements.
Unfortunately, not all requests can be met, but we will assess each application on its merits and will prioritise those requests which are aligned to our therapy areas and focus on supporting scientific and non-profit and charitable organisations who directly support a commitment to improving the lives of patients and ongoing medical and scientific research and education.
[As a general rule, we are not able to support requests from individuals for their personal ongoing education].
Submit your application today.
Learn How on Our U.S. Corporate Website
NO-GB-2100024
Date of preparation: February 2021